Fig. 3

Overview of differentially expressed genes and top-ranked altered pathways across all patient-matched metastasis pairs. The x-axis shows each individual metastasis pair grouped by and color-coded according to the tissue in which the extracranial metastasis occurred (blue: lymph node, green: lung, yellow: soft tissue, purple: skin, pink: liver, cyan: small intestine). A, Absolute number of genes with increased expression in each intracranial metastasis compared to the corresponding extracranial metastasis (red bars) and the absolute number of genes with decreased expression in each intracranial metastasis compared to the extracranial metastasis (blue bars). B, Percentage of genes associated with the top six cancer-relevant signaling pathways that were either increased or decreased expressed in the intracranial metastasis compared to the corresponding extracranial metastasis of a patient-matched metastasis pair. C, Percentage of genes associated with the top four immune-relevant pathways that were either increased or decreased expressed in the intracranial metastasis compared to the corresponding extracranial metastasis of a patient-matched metastasis pair. Significant enrichment of decreased or increased expressed genes in pathways of subpanels B and C are marked with ’x’ (FDR-adjusted p-value < 0.05)